Estimates indicate that approximately one in 10,000 males are born with hemophilia. This inherited bleeding disorder impairs the body’s ability to form blood clots properly, leading to prolonged bleeding after injuries, surgery, or trauma. The condition arises from a deficiency or absence of specific clotting factors, most commonly factor VIII (hemophilia A) or factor IX (hemophilia B).
Understanding the prevalence of hemophilia is crucial for public health planning, resource allocation, and genetic counseling. Accurate epidemiological data informs decisions regarding the production and distribution of clotting factor concentrates, the development of specialized treatment centers, and the implementation of preventative care programs. Historically, limited access to treatment led to significant morbidity and mortality among affected individuals. However, advancements in medical care have dramatically improved the life expectancy and quality of life for those living with the condition.
